NY-TOM-FORD
18.9.2023 14:01:30 CEST | Business Wire | Press release
TOM FORD announced today that Rebecca Mason has been appointed Senior Vice President, Global Brand Image and Paolo Cigognini has been appointed Senior Vice President, Global Communications and Media, effective August 28, 2023. The new leaders will work closely together to ensure brand image and communications are consistent and cohesive across all verticals of the global luxury house including fashion, beauty and eyewear.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230917506746/en/
Rebecca Mason joins TOM FORD as Senior Vice President, Global Brand Image (Photo: Business Wire)
Mason joins TOM FORD following a multi-faceted career at Condé Nast, where she spent more than 15 years, most recently as Vice President of Global Creative for Condé Nast Commercial Creative. As Senior Vice President, Global Brand Image, TOM FORD, Mason will oversee the brand image for all TOM FORD categories, ensuring the signature global luxury brand image and philosophy are cohesively expressed across all touchpoints. Mason will report to Guillaume Jesel, President and CEO, TOM FORD with matrix reporting to Peter Hawkings, Creative Director, TOM FORD.
“An exceptional brand steward, Rebecca brings a deep understanding of luxury brand storytelling. Her proven expertise will ensure that the brand image of TOM FORD continues to deliver visually arresting, bold concepts that elevate the iconic TOM FORD vision of modern luxury glamour,” said Jesel.
Cigognini joins TOM FORD with twenty years of global luxury marketing and communications experience. Previously, Cigognini served as Chief Marketing Officer at Alexander McQueen and held leadership roles in marketing and communications at Bottega Veneta, Dolce & Gabbana, and Bulgari. As Senior Vice President, Global Communications and Media, Cigognini will oversee brand equity, strategic communications, paid, owned and earned media, talent and brand voice, for all categories of TOM FORD. Cigognini will report to Guillaume Jesel with matrix reporting to Lelio Gavazza, CEO of TOM FORD FASHION.
“Paolo is a world class, strategic communications leader with exceptional experience working with Creative Directors in fashion. He has deep expertise in driving luxury aspiration and elevating brand equity to deliver business results,” said Gavazza.
ABOUT TOM FORD
TOM FORD is a global luxury house offering exceptional women’s and men’s fashion, accessories, eyewear and beauty. Founded in 2005 by Tom Ford, the brand is known for modern luxury glamour. In 2023, Peter Hawkings was appointed Creative Director. The Estée Lauder Companies is the sole owner of TOM FORD and has long-term licenses with Ermenegildo Zegna NV for TOM FORD FASHION and Marcolin Group for TOM FORD EYEWEAR.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230917506746/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 07:30:00 CET | Press release
Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob
Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 06:30:00 CET | Press release
Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan
VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 01:00:00 CET | Press release
Enabling Next-Generation High-Performance Automotive Camera Systems VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise
Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 22:30:00 CET | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that
Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 22:30:00 CET | Press release
Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
